Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

finscreener linkedin page

Cytokinetics, Incorporated

TRADE

NASDAQ: CYTKHealthcare / Biotechnology / USA
8.66+1.04+13.65%Vol 434 2971Y Perf -43.51%
Oct 16th, 2018 16:00
BID8.65 ASK8.66
Open7.71 Previous Close7.62
Pre-Market- After-Trading8.65
 - -%  -0.01 -0.12%
Target Price
14.00 
Analyst Rating
Moderate Buy 1.60
Potencial %
61.66 
Finscreener Ranking
+     36.98
Insiders Trans % 3/6/12M
-100/-100/-100 
Value Ranking
+     35.50
Insiders Value % 3/6/12M
-100/-100/-100 
Growth Ranking
     37.42
Insiders Shares Cnt. % 3/6/12M
-100/-100/-100 
Income Ranking
 —    -
Market Cap (mil)473 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
26.03 
Earnings Date
25th Oct 2018

Today's Price Range

7.658.75

 

52wk Range

6.2015.65

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
5.61%
3 Months
-1.59%
6 Months
10.32%
1 Year
-43.51%
3 Years
23.89%
5 Years
22.32%

Quotes

Name / TickerPriceChg.Chg.%
CYTK8.661.040013.65
AAPL222.154.79002.20
GOOG1 121.2829.03002.66
MSFT111.003.40003.16
XOM81.200.38000.47
WFC53.730.49000.92
JNJ136.562.61001.95
FB158.785.26003.43
GE12.10-0.0500-0.41
JPM108.622.28002.14
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 8.50
Current Ratio 9.00
Long Term Debt to Total Capital 0.29
Total Debt to Equity 0.43
Interest Coverage -5.60
Leverage Ratio 3.60
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin-
EBIT Margin-628.90
EBITDA Margin-615.60
Pre-tax Profit Margin-242.50
Profit Margin-96.41
ValuationValueIndustryS&P 500US Markets
PE Ratio 473.30
PB Ratio 5.53
PS Ratios 36.26
Price to Cash Flow 2 571.50
Price to Free Cash Flow -5.10
Cash Flow Per Share -1.97
Price to Tangible Book5.53
Book Value per Share1.38
Enterprise Value (in ths.)216 143
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-47.53
ROE last 12 Months -102.81
Return on Assets (5Y Avg) -12.71
ROA last 12 Months -43.87
Return on Capital (5Y Avg) -36.46
ROC last 12 Months -73.23
Return on invested Capital Q -19.45
Return on invested Capital Y-86.11
Assets Turnover0.10
Receivables Turnover85.10
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)11 465
Revenue per Share 0.21
Revenue Growth 3 Years -23.98
Revenue Growth 5 Years 2.01
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q02 2018-0.49-0.51-4.08
Q01 2018-0.53-0.56-5.66
Q04 2017-0.71-0.75-5.63
Q03 2017-0.64-0.606.25
Q02 2017-0.66-0.609.09
Q01 2017-0.11-0.62-463.64
Q04 2016-0.270.16159.26
Q03 2016-0.270.74374.07
Earnings Per EndEstimateRevision %Trend
9/2018 QR-0.53-12.77Negative
12/2018 QR-0.55-12.24Negative
12/2018 FY-2.06-4.57Negative
12/2019 FY-1.846.12Positive
Next Report Date25th Oct 2018
Estimated EPS Next Report-0.53
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume434 297
Shares Outstanding (in ths.)54 630
Trades Count1 852
Dollar Volume3 248 891
Avg. Volume326 412
Avg. Weekly Volume231 981
Avg. Monthly Volume328 065
Avg. Quarterly Volume270 014

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

30%70%

Bearish Bullish

74%26%

Bearish Bullish

63%37%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
3 (60.00 %)
3 (60.00 %)
Moderate Buy
1 (20.00 %)
1 (20.00 %)
2 (40.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
1.60
Moderate Buy
1.60
Strong Buy
1.30

There are no comments yet.

News

x